Galena’s Past Marketing of Abstral Prompts DOJ, FDA Probes

January 18, 2017

Galena Biopharma announced that the U.S. Attorney’s Office for the District of New Jersey and the Justice Department have started criminal investigations related to the marketing and promotion of the opioid drug Abstral.

A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the False Claims Act and other federal statutes.

According to Galena, the FDA and other government agencies are also investigating their Abstral promotion practices.

View today's stories